Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aldeyra Therapeutics

2.66
+0.21008.57%
Post-market: 2.61-0.0500-1.88%19:43 EDT
Volume:662.05K
Turnover:1.72M
Market Cap:159.32M
PE:-2.75
High:2.67
Open:2.51
Low:2.47
Close:2.45
Loading ...

Aldeyra options imply 35.3% move in share price post-earnings

TIPRANKS
·
04 Apr

Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall

Benzinga
·
03 Apr

Aldeyra Therapeutics Shares Fall 74% as FDA Declines to Approve Co's Eye Disease Drug

THOMSON REUTERS
·
03 Apr

Aldeyra Therapeutics Gets US FDA Letter for Resubmission of New Drug Application for Eye Disease Treatment - Shares Slump Pre-Bell

MT Newswires Live
·
03 Apr

Aldeyra down 75% after receiving CRL from FDA for reproxalap

TIPRANKS
·
03 Apr

BUZZ-Aldeyra Therapeutics falls over 70% as FDA declines to approve eye disease drug

Reuters
·
03 Apr

BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease

Reuters
·
03 Apr

US FDA declines to approve Aldeyra's eye disease drug

Reuters
·
03 Apr

Aldeyra Therapeutics Inc -New Drug Application Resubmission Expected Mid-Year 2025

THOMSON REUTERS
·
03 Apr

Aldeyra Therapeutics Inc -Top-Line Data From Dry Eye Chamber Trial and Field Trial Expected in Q2 2025

THOMSON REUTERS
·
03 Apr

Aldeyra Therapeutics - Letter Identified Concerns With Data From Trial Submitted to Nda That May Have Affected Interpretation of Results

THOMSON REUTERS
·
03 Apr

Aldeyra Therapeutics Receives Complete Response Letter From the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

THOMSON REUTERS
·
03 Apr

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Business Wire
·
03 Apr

Aldeyra options imply 29.5% move in share price post-earnings

TIPRANKS
·
28 Mar

High Growth Tech Stocks To Watch In The US March 2025

Simply Wall St.
·
11 Mar

Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference

Business Wire
·
10 Mar

Aldeyra Therapeutics: Strategic Pipeline Advancements and Financial Stability Drive Buy Rating

TIPRANKS
·
07 Mar

Aldeyra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Aldeyra Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
04 Mar

Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar